Sacubitril-valsartan cocrystal revisited: role of polymer excipients in the formulation

References

• Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Design. 2009;9(6):2950–2967.
   PubMed Web of Science ®Google Scholar
• Duggirala NK, Vyas A, Krzyzaniak JF, et al. Mechanistic insight into caffeine-oxalic cocrystal dissociation in formulations: role of excipients. Mol Pharm. 2017 Nov 6;14(11):3879–3887.
   PubMed Web of Science ®Google Scholar
• Koranne S, Sahoo A, Krzyzaniak JF, et al. Challenges in transitioning cocrystals from bench to bedside: dissociation in prototype drug product environment. Mol Pharm. 2018 Aug 6;15(8):3297–3307.
   PubMed Web of Science ®Google Scholar
• Emami S, Siahi-Shadbad M, Adibkia K, et al. Recent advances in improving oral drug bioavailability by cocrystals. Bioimpacts. 2018;8(4):305–320.
   PubMed Web of Science ®Google Scholar
• Wang J-R, Wang X, Yang Y, et al. Solid-state characterization of 17β-estradiol co-crystals presenting improved dissolution and bioavailability. CrystEngComm. 2016;18(19):3498–3505.
   Web of Science ®Google Scholar
• He H, Zhang Q, Li M, et al. Modulating the dissolution and mechanical properties of resveratrol by cocrystallization. Cryst Growth Des. 2017;17(7):3989–3996.
   Web of Science ®Google Scholar
• Chen Y, Li L, Yao J, et al. Improving the solubility and bioavailability of apixaban via apixaban–oxalic acid cocrystal. Cryst Growth Des. 2016;16(5):2923–2930.
   Web of Science ®Google Scholar
• Wang J-R, Yu X, Zhou C, et al. Improving the dissolution and bioavailability of 6-mercaptopurine via co-crystallization with isonicotinamide. Bioorg Med Chem Lett. 2015;25(5): 1036–1039.
   PubMed Web of Science ®Google Scholar
• Zhu B, Zhang Q, Wang J-R, et al. Cocrystals of baicalein with higher solubility and enhanced bioavailability. Cryst Growth Des. 2017;17(4):1893–1901.
   Web of Science ®Google Scholar
• Warren DB, Benameur H, Porter CJ, et al. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. J Drug Target. 2010 Dec;18(10):704–731.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang K, Hamill N, et al. Investigating the influence of polymers on supersaturated flufenamic acid cocrystal solutions. Mol Pharm. 2016 Sep 6;13(9):3292–3307.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang K, Qiao N, et al. Investigating permeation behavior of flufenamic acid cocrystals using a dissolution and permeation system. Mol Pharm. 2018 Sep 4;15(9):4257–4272.
   PubMed Web of Science ®Google Scholar
• Guo M, Wang K, Qiao N, et al. Insight into flufenamic acid cocrystal dissolution in the presence of a polymer in solution: from single crystal to powder dissolution. Mol Pharm. 2017 Dec 4;14(12):4583–4596.
   PubMed Web of Science ®Google Scholar
• Lipert MP, Rodriguez-Hornedo N. Cocrystal transition points: role of cocrystal solubility, drug solubility, and solubilizing agents. Mol Pharm. 2015 Oct;12(10):3535–3546.
   PubMed Web of Science ®Google Scholar
• Hou X, Tong Q, Wang W, et al. Dihydromyricetin protects endothelial cells from hydrogen peroxide-induced oxidative stress damage by regulating mitochondrial pathways. Life Sci. 2015;130:38–46.
   PubMed Web of Science ®Google Scholar
• Yamashita H, Sun CC. Expedited tablet formulation development of a highly soluble carbamazepine cocrystal enabled by precipitation inhibition in diffusion layer. Pharm Res. 2019 Jun;36(6).
   Google Scholar
• Hasa D, Rauber GS, Voinovich D, et al. Cocrystal formation through mechanochemistry: from neat and liquid-assisted grinding to polymer-assisted grinding. Angew Chem. 2015 Jun 15;54(25):7371–7375.
   Google Scholar
• Boksa K, Otte A, Pinal R. Matrix-assisted cocrystallization (MAC) simultaneous production and formulation of pharmaceutical cocrystals by hot-melt extrusion. J Pharm Sci. 2014 Sep;103(9):2904–2910.
   PubMed Web of Science ®Google Scholar
• Sanphui P, Rajput L. Tuning solubility and stability of hydrochlorothiazide co-crystals. Acta Crystallogr Sect B: Struct Sci, Cryst Eng Mater. 2014;70(1):81–90.
   Google Scholar
• Stanton MK, Bak A. Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Cryst Growth Design. 2008;8(10):3856–3862.
   Web of Science ®Google Scholar
• Stanton MK, Tufekcic S, Morgan C, et al. Drug substance and former structure property relationships in 15 diverse pharmaceutical co-crystals. Cryst Growth Design. 2009;9(3):1344–1352.
   Web of Science ®Google Scholar
• Koranne S, Krzyzaniak JF, Luthra S, et al. Role of coformer and excipient properties on the solid-state stability of theophylline cocrystals. Cryst Growth Des. 2019;19(2):868–875.
   Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual‐acting angiotensin receptor—neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–414.
   PubMed Web of Science ®Google Scholar
• Feng L, Karpinski PH, Sutton P, et al. LCZ696: a dual-acting sodium supramolecular complex. Tetrahedron Lett. 2012;53(3):275–276.
   Web of Science ®Google Scholar
• Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133(11):1115–1124.
   PubMed Web of Science ®Google Scholar
• Dansereau R, Brock M, Redman-Furey N. The solubilization of drug and excipient into a hydroxypropyl methylcellulose (HPMC)-based film coating as a function for the coating parameters in a 24” accela-cota®. Drug Dev Ind Pharm. 1993;19(7):793–808.
   Web of Science ®Google Scholar
• Konno H, Taylor LS. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci. 2006;95(12):2692–2705.
   PubMed Web of Science ®Google Scholar
• Ambike AA, Mahadik K, Paradkar A. Stability study of amorphous valdecoxib. Int J Pharm. 2004;282(1–2):151–162.
   PubMed Web of Science ®Google Scholar
• Jarray A, Gerbaud V, Hemati M. Structure of aqueous colloidal formulations used in coating and agglomeration processes: mesoscale model and experiments. Powder Technol. 2016;291:244–261.
   Web of Science ®Google Scholar
• Keepers JW, James TL. A theoretical study of distance determinations from NMR. Two-dimensional nuclear overhauser effect spectra. J Magn Reson (1969). 1984;57(3):404–426.
   Web of Science ®Google Scholar
• Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. Faseb J. 2008 Mar;22(3):659–661.
   PubMed Web of Science ®Google Scholar
• Frisch MJ, Trucks GW, Schlegel HB, et al. Gaussian 09, Revision A.02. Wallingford CT: Gaussian, Inc.; 2016.
   Google Scholar
• Case DA, Ben-Shalom IY, Brozell SR, et al. AMBER 2018. San Francisco: University of California; 2018.
   Google Scholar
• Wang J, Wolf RM, Caldwell JW, et al. Development and testing of a general amber force field. J Comput Chem. 2004;25(9):1157–1174.
   PubMed Web of Science ®Google Scholar
• Wang H, Gao Z, Song P, et al. Molecular dynamics simulation and QM/MM calculation reveal the selectivity mechanism of type I 1/2 kinase inhibitors: the effect of intramolecular H-bonds and conformational restriction for improved selectivity. Phys Chem Chem Phys. 2019 Nov 21;21(43):24147–24164.
   PubMed Web of Science ®Google Scholar
• Skotnicki M, Gawel A, Cebe P, et al. Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry. Drug Dev Ind Pharm. 2013 Oct;39(10):1508–1514.
   PubMed Web of Science ®Google Scholar
• Brittain HG. Vibrational spectroscopic studies of cocrystals and salts. 2. The benzylamine− benzoic acid system. Cryst Growth Design. 2009;9(8):3497–3503.
   Web of Science ®Google Scholar
• Sampath A, Reddy AR, Yakambaram B, et al. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist. J Pharm Biomed Anal. 2009;50(3):405–412.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–420.
   PubMed Web of Science ®Google Scholar
• Borbas E, Sinko B, Tsinman O, et al. Investigation and mathematical description of the real driving force of passive transport of drug molecules from supersaturated solutions. Mol Pharm. 2016 Nov 7;13(11):3816–3826.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Tocher DA, Price SL. Computational prediction of salt and cocrystal structures—Does a proton position matter? Int J Pharm. 2011;418(2):187–198.
   PubMed Web of Science ®Google Scholar
• Potamitis C, Zervou M, Katsiaras V, et al. Antihypertensive drug valsartan in solution and at the AT1 receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations. J Chem Inf Model. 2009;49(3):726–739.
   PubMed Web of Science ®Google Scholar
• Gilli G, Gilli P. The nature of the hydrogen bond: outline of a comprehensive hydrogen bond theory. Vol. 23. New York: Oxford University Press; 2009.
   Google Scholar
• Yamamoto T, Komarudin D, Arai M, et al. Extensive studies on π-stacking of poly (3-alkylthiophene-2, 5-diyl) s and poly (4-alkylthiazole-2, 5-diyl) s by optical spectroscopy, NMR analysis, light scattering analysis, and X-ray crystallography. J Am Chem Soc. 1998;120(9):2047–2058.
   Web of Science ®Google Scholar
• Márquez-Miranda V, Camarada MB, Araya-Durán I, et al. Biomimetics: from bioinformatics to rational design of dendrimers as gene carriers. Plos One. 2015;10(9):e0138392.
   PubMed Web of Science ®Google Scholar
• Dahan A, Beig A, Lindley D, et al. The solubility–permeability interplay and oral drug formulation design: two heads are better than one. Adv Drug Deliv Rev. 2016;101:99–107.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz I. The search for an effective HFpEF treatment continues. Nat Rev Cardiol. 2019 Nov;16(11):647.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Ferretti V, Dalpiaz A, Bertolasi V, et al. Indomethacin co-crystals and their parent mixtures: does the intestinal barrier recognize them differently? Mol Pharm. 2015 May;12(5):1501–1511.
   PubMed Web of Science ®Google Scholar